We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Alliance Pharmaceutical, through its subsidiary PFC Therapeutics, and Beijing
Double-Crane Pharmaceutical ("Double-Crane"), today announced that
they have entered into a Memorandum of Understanding ("MOU") for the
development of Oxygent in The People's Republic of China ("PRC").
Florida Attorney General Charlie Crist has sued three pharmaceutical companies
for $25 million, charging them with illegally inflating prices on generic drugs
used to treat depression, schizophrenia, seizures and angina.
Swiss Medica (is pleased to announce its business relationship with two distinguished
Massachusetts Institute of Technology scientists through its recent acquisition
of Anti-Depression BioHealth Solutions Inc.
Takeda Pharmaceutical and Toray Industries announced today that the companies
have concluded a joint development and marketing agreement on an investigational
compound for frequent urination/urinary incontinence.
Pharmaceutical giant Pfizer said yesterday it has no immediate plans to axe
jobs in Ireland as part of its global cost-cutting program. The company, which
employs 1,800 people in Ireland, is seeking to slash costs by 3.1 billion euros
a year globally.
Gov. Rod Blagojevich is awarding $15 million in grants and tax credits to Takeda
Pharmaceuticals North America Inc. in return for adding 500 new jobs. The money
will help Takeda build a 1.2 million-square-foot campus in Deerfield on a 70-acre
property the company bought in December 2002.
The manufacturers of multiple sclerosis (MS) drug Tysabri confirmed late March
30 that the drug has been linked to a third case of a deadly central nervous
system disorder - news that analysts believe could close the door on the drug's
potential return to the market.
Asthma inhalers using chlorofluorocarbon (CFC) propellants must be phased out
by 2009, according to an FDA final rule that gives manufacturers significantly
more time to make the transition to CFC-free products than some experts had
recommended.
Barr Laboratories is taking the plunge into the follow-on biologics market,
announcing March 30 that it is partnering with Croatian biopharmaceutical firm
PLIVA to develop its first biogeneric product.